NEW YORK– Clearmind Medicine Inc. a biotech firm dedicated to the discovery and development of novel psychedelic-derived therapeutics, has taken significant steps to enhance its intellectual property (IP) portfolio through the submission of three patent applications under the international Patent Cooperation Treaty (PCT). This strategic move, in collaboration with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company specializing in central nervous system disorders, underscores the companies’ commitment to advancing the field of psychedelic medicine.
The patent applications encompass innovative proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), and Palmitoylethanolamide (PEA), the active ingredient in SciSparc’s proprietary CannAmide™. Initially filed as provisional patents with the United States Patent and Trademark Office (USPTO), these applications represent Clearmind’s continuous effort to secure robust IP protection for its groundbreaking compounds on a global scale.
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind, highlighted the importance of these developments, stating, “Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry. The PCT applications strengthen our position, enabling us to pursue patent protection in numerous countries simultaneously. Our collaboration with SciSparc has been fruitful, leading to 11 patent applications to date and positioning us as leaders in psychedelic research and the development of safer, more effective treatments.”
The expansion of Clearmind’s IP portfolio, now boasting 27 granted patents and 24 pending applications across 15 families, reflects the company’s strategic emphasis on securing comprehensive protection for its innovations. With patents granted in key markets including the US, Europe, China, and India, Clearmind underscores its global approach to revolutionizing treatment modalities for under-treated health issues such as alcohol use disorder.
Clearmind Medicine Inc. remains focused on leveraging its extensive patent portfolio and cutting-edge research to develop and commercialize psychedelic-based compounds as regulated medicines, supplements, or foods. The company’s shares are traded on Nasdaq, the Canadian Securities Exchange (CSE), and the Frankfurt Stock Exchange, reflecting its broad appeal to investors and its commitment to addressing pressing health challenges through innovative therapeutics.
